1. Maize JC, Ahmed AR, Provost TT. Xanthoma Disseminatum and Multiple Myeloma. Arch Dermatol 1974;110:758‑61.

2. Ahmed AR, Chu TM. Letter: Carcinoembryonic Antigen in Dermatoses. Lancet 1976;2:309-10.

3. Ahmed AR, Winkler NW. Psoriasis and Bullous Pemphigoid. Arch Dermatol 1977;113:845.

4. Ahmed AR, Chu TM, Provost TT. Bullous Pemphigoid: Clinical and Serological Evaluation for Associated Malignant Neoplasms. Arch Dermatol 1977;113:969.

5. Ahmed AR, Maize JC, Provost TT. Bullous Pemphigoid. Clinical and Immunologic Follow‑up After Successful Therapy. Arch Dermatol 1977;113:1043‑6.

6. Ahmed AR, Cohen E, Blumenson LE, Provost TT. HLA in Bullous Pemphigoid. Arch Dermatol 1977;113:1121.

7. Provost TT, Ahmed AR, Maddison PJ, Reichlin M. Antibodies to Cytoplasmic Antigens in Lupus Erythematosus. Serologic Marker for Systemic Disease. Arch and Rheum 1977;20:1457‑63.

8. Rasmussen JE, Ahmed AR. Trichophyton Reactions in Children with Tinea Capitus. Arch Dermatol 1978;114:371‑2.

9. Ahmed AR, Provost TT. Incidence of a Positive Lupus Band Test Using Sun-Exposed and Unexposed Skin. Arch Dermatol 1979;115:228‑9.

10. Provost TT, Maize JC, Ahmed AR, Strauss JS, Dobson RL. Unusual Subepidermal Bullous Diseases with Immunologic Features of Bullous Pemphigoid. Arch Dermatol 1979;115:156‑60.

11. Ahmed AR. Role of pemphigus antibody titres in treating pemphigus. West J Med 1979;130:62.

12. Ahmed AR. Langerhans cells – epidermal macrophage. West J Med 1979;130:162.

13. Park MS, Terasaki PI, Ahmed AR, Tiwari JL. HLA-DRW4 in 91% Jewish pemphigus vulgaris patients. Lancet 1979;2:441-2.

14. Arnold AJ, Simpson JG, Jones HE, Ahmed AR. Suppression of histamine-induced pruritus by hydroxyzine and various neuroleptics. J Am Acad Dermatol 1979;1:509‑12.

15. Moderator: Ahmed AR. Discussants: Graham J, Jordon RE, Provost TT. Los Angeles, CA.  Pemphigus: Current Concepts. Ann Intern Med 1980;92:396‑405.

16. Drenick, EJ, Ahmed AR, Greenway F, Olerud JE. Cutaneous Lesions after Intestinal Bypass. Ann Intern Med 1980;93:557‑9.

17. Thompson JW, Ahmed AR, Dudley JP. Epidermolysis bullosa dystrophica of the larynx and trachea. Acute airway obstruction. Ann Otol Rhinol Laryngol 1980;89:428‑9.

18. Ahmed AR, Kaplan R. Pruritic urticarial papules and plaques of pregnancy. J Am Acad Dermatol 1981;4:679‑81.

19. Ahmed AR. Lymphocyte Studies in Pemphigus. Arch Dermatol Res 1981;271:111‑5.

20. Ahmed AR., Murahata R. Detection of Pemphigus-like Antigens on Tumor Cell Lines. Arch Dermatol Res 1981;271:441‑5.

21. Kaplan RP, Touloukian J, Ahmed AR, Newcomer VD. Esophagitis dissecans superficialis associated with pemphigus vulgaris. J Am Acad Dermatol 1981;4:682‑7.

22. Ahmed AR, Moy R. Treatment of acquired cold urticaria with azatadine. Aust J Derm 1981;22:53-5.

23. Rapaport MJ, Ahmed AR. Falsely Normal Direct Immunofluorescent Microscopic Findings in Bullous Impetigo. Arch Dermatol 1981;117:524.

24. Ahmed AR. Lymphocyte studies in bullous pemphigoid. J Dermatol 1981;8:385‑9.

25. Ahmed AR, Moy R, Barr AR, Price Z. Carpet beetle dermatitis. J Am Acad Dermatol 1981;5:428‑32.

26. Ahmed AR, Strom H, Bierman S, Myers‑Elliot R, Tiwari P, Terasaki PI. A study of HLA and DRw antigens in severe recurrent herpes progenitalis (HSV-2) infection. J Am Acad Dermatol 1982;6:898‑901.

27. Ahmed AR, Sofen H, Saxon AS. Detection of an Antisquamous Antibody in Multiple Keratoacanthoma. Clin Immunol Immunopathol 1982;22:20‑31.

28. Ahmed AR. Lymphocyte Studies in Bechet’s Syndrome. Dermatologica 1982;164:175‑80.

29. Ahmed AR, Moy R. Chronic Bullous Dermatosis of Childhood. Linear IgA Bullous dermatosis. Am J Dis Child 1982;136:214‑7.

30. Ahmed AR. Antibody-dependent cellular cytotoxicity in bullous diseases. J Am Acad Dermatol 1982;6:481‑4.

31. Ahmed AR, Ank BJ, Gard SE, Stiehm ER. Bactericidal activity and chemotaxis in pemphigus vulgaris and bullous pemphigoid. J Am Acad Dermatol 1982;6:1028-33.

32. Ahmed AR, Sofen H. Familial Occurrence of Pemphigus Vulgaris. Arch Dermatol 1982;118:423‑4.

33. Ahmed AR, Stevens RH, Saxon A. Production of Anti‑Basement Membrane-Zone Antibody by Peripheral Blood Leukocytes of Bullous Pemphigoid Patients. J Clin Immunol 1982;2:179‑85.

34. Ahmed AR, Moy R. Death in pemphigus. J Am Acad Dermatol 1982;7:221‑8.

35. Murahata RI, Ahmed AR. Detection of Class-Specific Antibodies of Pemphigus Vulgaris Using a Solid Phase Radioimmunoassay. J Invest Dermatol 1982;79:65‑8.

36. Ahmed AR, Drenick EJ. Cutaneous immunofluorescence studies in bowel bypass syndrome. Clin Exp Dermatol 1982;7:477‑83.

37. Ahmed AR, Schreiber P, Abramovits W, Ostreicher M, and Lowe NJ. Coexistence of lichen planus and systemic lupus erythematosus. J Am Acad Dermatol 1982;7:478‑83.

38. Ahmed AR, Kaplan RP, Hardy D, Hardy D, Feldman E, Pitt H. Bullous Pemphigoid and Ulcerative Colitis. Int J Dermatol 1982;21:594‑8.

39. Ahmed AR, Workman S. Pemphigus‑like antibodies. Arch Dermatol 1983;119:17‑21.

40. Ahmed A, Workman S. Anti-Intercellular Substance Antibodies. Presence in Serum Samples of 14 Patients Without Pemphigus. Arch Dermatol 1983;119:17-21

41. Jeffes EWB, Yamamoto RS, Ahmed AR, Granger GA. Lymphotoxin Detected in the Blister Fluid of Bullous Pemphigoid Patients. J Clin Immunol 1984;4:31-5.

42. Cochran A, Nestor MS, Groopman JE, Ahmed AR. Tumor infiltrates in acquired immunodeficiency syndrome patients with Kaposi’s Sarcoma. Lancet 1983;1:416.

43. Shaw DW, Hocking W, Ahmed AR. Generalized Cutaneous Mastocytosis and Acute Myelogenous Leukemia. Int J Dermatol 1983;22:109‑12.

44. Ahmed AR, Stevens RH. An Autoradiographic Technique to Evaluate in vitro Produced Autoantibodies by Peripheral Blood Leukocytes of Patients with Bullous Pemphigoid. Arch Dermatol Res 1983;275:59‑61.

45. Ahmed AR, Moy RL, Chia D, Barnett EV. Immune Complexes in Pemphigus and Bullous Pemphigoid. Dermatologica 1983;166:175‑80.

46. Murahata RI and Ahmed AR. Partial Purification and Characterization of Pemphigus‑like Antigens in Urine. Arch Dermatol Res 1983;275:118‑23.

47. Ahmed AR and Salm M. Juvenile pemphigus. J Am Acad Dermatol 1983;8:799‑807.

48. Ahmed AR, Aiello J. Chronic tinea pedis: presence of high serum IgE levels, anti‑ICS antibody and ANA. Clin Exp Dermatol 1983; 8:415‑20.

49. Ahmed AR, Murahata RI, Schroff RW, Stevens RM, Saxon AS. Production of Pemphigus Antibody in vitro and Analysis of T-Cell Subsets. J Clin Immunol 1983;3:241-52.

50. Ahmed AR. Autoradiographic technique to study in vitro produced autoantibodies in pemphigus vulgaris. Arch Dermatol Res 1983;275:204‑6.

51. Bevan HJ, Murahata RI, Ahmed AR. Detection of anti-intercellular cement substance and anti-basement membrane zone antibodies by radioimmunoassay using SCaBER tumor cell line as substrate. Brit J Dermatol 1983;109:261‑5.

52. Oikarinen AI, Zone JJ, Ahmed AR, Kiistala U, Uitto J. Demonstration of Collagenase and Elastase Activities in the Blister Fluids from Bullous Skin Diseases. Comparison Between Dermatitis Herpetiformis and Bullous Pemphigoid. J Invest Dermatol 1983;81:261‑6.

53. Park MS, Terasaki PI, Ahmed AR and Zone J. The 90% incidence of HLA antigen (Te24) in dermatitis herpetiformis. Tissue Antigens 1983;22:263‑6.

54. Ahmed AR, Konqui AS, Park MS, Tiwari JL, Terasaki PI. DR Antigens in Bullous Pemphigoid. Arch Dermatol 1984;120:795

55. Ahmed AR, Salm M. Localized Cicatricial Pemphigoid (Burnstig‑Perry): A Transplantation Experiment. Arch Derm 1984;120:932‑5.

56. Amerian ML, Ahmed AR. Pemphigus erythematosus. Presentation of four cases and review of literature. J Am Acad Dermatol 1984;10:215-22.

57. Ahmed AR, Blose DA. Pemphigus Vegetans. Neumann Type and Hallopeau Type. Int J Dermatol 1984;23:135‑41.

58. Kirmani-Arab V, Hijri K, Ahmed AR, Fahey JL. Deficiency of Interleukin-2 Production and Interleukin-2 Receptor Expression on Peripheral Blood Leucocytes after Phytohemagglutinin Stimulation in Pemphigus. J Invest Dermatol 1984;83:101‑4.

59. Ahmed AR, Hijri K, and Arab-Kermani V. Interleukin-2 Production in Bullous Pemphigoid. Arch Dermatol Res 1984;276:330‑2.

60. Jeffes EWB,III, Kaplan RP, and Ahmed AR. Acantholysis Produced in Vitro with Pemphigus Serum: Hydrocortisone Inhibits Acantholysis, While Dapsone and 6‑Mercaptopurine Do Not Inhibit Acantholysis. J Clin Immunol 1984;4:359‑63.

61. Ellison DE, Ward PH, Ahmed AR. Pemphigus and bullous pemphigoid of upper aerodigestive tract. Trans Am Laryngol Assoc 1984:105;132‑9.

62. Ahmed AR, Schreiber P, Aiello J, Tiwari JL, Terasaki PI. A preliminary report on the role of some immunologic factors in persistence of chronic tinea pedis. Clin Exp Dermatol 1985;10:45‑50.

63. Ahmed AR, Bevan HJ, and Murhata RI. Clinical correlations of antibodies in pemphigus studied by radioimmunoassay. J Am Acad Dermatol 1985;12:45‑51.

64. Simjee S, Konqui A, Ahmed AR. Multiple Sclerosis and Bullous Pemphigoid. Dermatologica 1985;170:86‑9.

65. Ahmed AR. Suppressor-Cell Functions in Bullous Pemphigoid. Arch Dermatol Res 1985;277:307‑12.

66. Rosove MH, Harwig SL, Ahmed AR. Dapsone and Heinz bodies. Arch Dermatol 1985;121:25.

67. Ahmed AR, Amerian ML. Correlation of Serum Anti‑Basement Membrane Zone Antibody and Malignancy in Bullous Pemphigoid. Dermatologica 1985;171:82‑5.

68. Borok M, Heng, MC, Ahmed AR. Epidermolysis Bullosa Acquisita in an 8-year-old Girl. Pediatr Dermatol 1986;3:315‑22.

69. Ahmed AR, Park MS, Tiwari JL, Terasaki PI. Association of DR4 with Pemphigus. Exp Clin Immunogenet 1987;4:8‑16.

70. Nestor MS, Cochran AJ, Ahmed AR. Mononuclear Cell Infiltrates in Bullous Disease. J Invest Dermatol 1987;88:172‑5.

71. Ahmed AR, Hombal S. Use of cyclophosphamide in azathioprine failures in pemphigus. J Am Acad Dermatol 1987;17:437‑42.

72. Kaufman AJ, Ahmed AR, Kaplan RP. Pemphigus, myasthenia gravis, and pregnancy. J Am Acad Dermatol 1988;19:414‑8.

73. Jeffes EWB III, Ahmed AR. Adjuvant therapy of bullous pemphigoid with Dapsone. Clin Exp Dermatol 1989;14:132‑6.

74. Zaltas MM, Ahmed R, Foster CS. Association of HLA‑DR4 with ocular cicatricial pemphigoid. Curr Eye Res 1989;8:184‑93.

75. Ahmed AR, Khan KNA, Wells P, Rice BA, Foster CS. Preliminary serological studies comparing immunofluorescence assay with radioimmunoassay. Curr Eye Res 1989;8:1011‑9.

76. Mirza NM, Mohimen A, Ahmed AR. Detection of pemphigus vulgaris antigen on COLO and SCaBER tumor cell lines by the immunoblot technique. Arch Derm Res 1990;282:418-20.

77. Ahmed AR, Yunis EJ, Alper CA. Complotypes in Pemphigus Vulgaris: Differences Between Jewish and Non‑Jewish Patients. Human Immunol 1990;27:298‑304.

78. Ahmed AR, Yunis EJ, Khatri K, Wagner R, Notani G, Awdeh Z, Alper CA. Major histocompatibility complex haplotype studies in Ashkenazi Jewish patients with pemphigus vulgaris. Proc Natl Acad Sci USA 1990;87:7658‑62.

79. Younus J, Ahmed AR. Autoimmunity and malignancy. J Am Acad Dermatol 1990;23:720-3.

80. Ahmed AR, Wagner R, Khatri K, Notani G, Awdeh Z, Alper CA Yunis EJ. Major histocompatibility complex haplotypes and class II genes in non‑Jewish patients with pemphigus vulgaris. (HLA/extended haplotypes/autoimmunity) Proc Natl Acad Sci USA 1991;88:5056‑60.

81. Wieselthier JS, Treloar V, Koh HK, Rao BK, Ahmed AR. Case Report: Multiple crusted plaques in a woman with systemic lupus erythematosus. Pemphigus erythematosus (PE). Arch Dermatol 1991;127:1572-6.

82. Ahmed AR, Foster S, Zaltas M, Notani G, Awdeh Z, Alper CA, Yunis EJ. Case Report: Association of DQw7 (DQB1*0301) with ocular cicatricial pemphigoid. Proc Natl Acad Sci USA 1991;88:11579‑82.

83. Haider N, Neuman R, Foster CS, Ahmed AR. Report on the sequence of DQB1*0301 gene in ocular cicatricial pemphigoid patients. Curr Eye Res 1992;11:1233‑8.

84. Ahmed AR, Mohimen A, Yunis EJ, Mirza NM, Kumar V, Beutner EH, Alper CA. Linkage of Pemphigus Vulgaris Antibody to the Major Histocompatibility Complex in Healthy Relatives of Patients. J Exp Med 1993;177:419‑424.

85. Mohimen A, Ahmed AR. Immunoblot assay to study the pemphigus vulgaris antigen in normal human epidermis and COLO‑16 cell line. Arch Dermatol Res 1993;285:165‑7.

86. Mohimen A, Narula M, Ruocco V, Pisani M, Ahmed AR. Presence of the autoantibody in healthy relatives of Italian patients with pemphigus vulgaris. Arch Dermatol Res 1993;285:176‑7.

87. Mohimen A, Neumann R, Foster CS, Ahmed AR. Detection and partial characterization of ocular cicatricial pemphigoid antigens on COLO and SCaBER tumor cell lines. Curr Eye Res 1993;12:741‑752.

88. Ahmed AR, Yunis JJ, Marcus-Bagley D, Yunis EJ, Salazar M, Katz AJ, Awdeh Z, Alper CA. Major Histocompatibility Complex Susceptibility Genes for Dermatitis Herpetiformis Compared with Those for Gluten-sensitive Enteropathy. J Exp Med 1993;178:2067‑75.

89. Bhol K, Mohimen A, Ahmed AR. Correlation of Subclasses of IgG with Disease Activity in Pemphigus Vulgaris. Dermatology 1994;189:85‑9.

90. Yunis JJ, Mobini N, Yunis EJ, Alper CA, Deulofeut R, Rodriguez A, Foster CS, Marcus-Bagley D, Good RA, Ahmed AR. Common major histocompatibility complex class II markers in clinical variants of cicatricial pemphigoid. Proc Natl Acad Sci USA 1994;91:7747‑51.

91. Firooz A, Mazhar A, Ahmed AR. Prevalence of autoimmune diseases in the family members of patients with pemphigus vulgaris. J Am Acad Dermatol 1994;31:434‑7.

92. Gibson WT, Walter MA, Ahmed AR, Alper CA, Cox DW. The immunoglobulin heavy chain and disease association: application to pemphigus vulgaris. Hum Genet 1994;94:675‑683.

93. Bhol K, Udel I, Haider N, Yunis JJ, Mohimen A, Neuman R, Grasso C, Ahmed AR,  Foster S. Ocular Cicatricial Pemphigoid. A Case Report of Monozygotic Twins Discordant for the Disease. Arch Ophthalmol 1995;113:202‑7.

94. Qureishi T, Nagarwalla N, Sarela A, Ahmed AR. Brief Communication. Antibodies to the 70-kDa Heat-Shock Protein in Patients with Thermal Burns. Clin Immunol Immunopathol 1995;75:94‑8.

95. Mohimen A, Ahmed AR. Comparison of an indirect immunofluorescence assay and a modified sensitive immunoblot assay for the study of the autoantibody in pemphigus vulgaris. Arch Dermatol Res 1995;287:202‑8.

96. Bhol K, Natarajan K, Nagarwalla N, Mohimen A, Aoki V, Ahmed AR. Correlation of peptide specificity and IgG subclass with pathogenic and nonpathogenic autoantibodies in pemphigus vulgaris: A model for autoimmunity. Proc Natl Acad Sci USA 1995;92:5239‑43.

97. Wucherpfennig KW, Yu B, Bhol K, Monos DS, Argyris E , Karr RW, Ahmed AR,  Strominger JL. Structural basis for major histocompatibility complex (MHC)-linked susceptibility to autoimmunity: Charged residues of a single MHC binding pocket confer selective presentation of self-peptides in pemphigus vulgaris. Proc Natl Acad Sci USA 1995;92:11935‑9.

98. Bhol K, Yunis J, Ahmed AR. Pemphigus vulgaris in distant relatives of two families: association with major histocompatibility complex class II genes. Clin Exp Dermatol 1996;21:100‑3.

99. Carson PJ, Hameed A, Ahmed AR. Influence of treatment on the clinical course of pemphigus vulgaris. J Am Acad Dermatol 1996;34:645-52.

100. Bhol K, Mohimen A, Neumann R, Yunis J, Foster CS, Yunis EJ, Ahmed AR. Differences in the anti-basement membrane zone antibodies in ocular and pseudo-ocular cicatricial pemphigoid. Curr Eye Res 1996;15:521‑32.

101. Buhac J, Bhol K, Padilla T Jr, Foster CS, Ahmed R. Coexistence of pemphigus vulgaris and ocular cicatricial pemphigoid. J Am Acad Dermatol 1996;34:884‑6.

102. Delgado JC, Turbay D, Yunis EJ, Yunis JJ, Morton ED, Bhol K, Norman R, Alper CA, Good RA, Ahmed R. A common major histocompatibility complex class II allele HLA‑DQB1*0301 is present in clinical variants of pemphigoid. Proc Natl Acad Sci USA 1996;93:8569‑71.

103. Delgado JC, Yunis DE, Bozon MV, Salazar M, Deulofeut R, Turbay D, Mehra NK, Pasricha JS, Raval RS, Patel H, Shah BK, Bhol K, Alper CA, Ahmed AR, Yunis EJ. MHC Class II alleles and haplotypes in patients with pemphigus vulgaris from India. Tissue Antigens 1996;48:668‑72.

104. Tyagi S, Bhol K, Natarajan K, Livir-Rallatos C, Foster CS, Ahmed AR. Ocular cicatricial pemphigoid antigen: Partial sequence and biochemical characterization. Proc Natl Acad Sci USA 1996;93:14714‑9.

105. Firooz A, Mobini N, Bahar K, Shams S, Ahmed AR, Dowlati Y. Presence of anti‑desmoglein 3 auto-antibodies in healthy relatives of Iranian patients with pemphigus vulgaris. The Gulf J Dermatol Venereol 1996;3:18‑20.

106. Firooz A, Mobini N, Bahar K, Shams S, Ahmed AR, Dowlati, Y. Antigenic specificities of Iranian patients with pemphigus vulgaris. Iranian J Med Sci 1996;21:47‑9.

107. Mobini N, Padilla T Jr, Ahmed AR. Long‑term remission in selected patients with pemphigus vulgaris treated with cyclosporine. J Am Acad Dermatol 1997;36:264‑6.

108. Ouahes N, Qureshi TA, Ahmed AR. Infertility in women with pemphigus vulgaris and other autoimmune diseases. J Am Acad Dermatol 1997;36:383‑7.

109. Mobini N, Yunis EJ, Alper CA, Yunis JJ, Delgado JC, Yunis DE, Firooz A, Dowlati Y, Bahar K, Gregersen PK, Ahmed AR. Identical MHC Markers in Non‑Jewish Iranian and Ashkenazi Jewish Patients with Pemphigus Vulgaris: Possible Common Central Asian Ancestral Origin. Hum Immunol 1997;57:62-7.

110. Delgado JC, Hameed A, Yunis JJ, Bhol K, Rojas AI, Rehman SB, Khan AA, Ahmad M, Alper CA, Ahmed AR, Yunis EJ. Pemphigus Vulgaris Autoantibody Response is Linked to HLA‑DQB1*0503 in Pakistani Patients. Hum Immunol 1997;57:110-9.

111. Qureshi WA, Asra Ali A, Bhol KC, Ahmed AR. Juvenile pemphigus foliaceus treated with sublesional corticosteroids. Int J Dermatol 1997;36:848-850.

112. Mobini N, Nagarwalla N, Ahmed AR. Oral pemphigoid. Subset of cicatricial pemphigoid? Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1998;85:37-43.

113. Bhol K, Tyagi S, Natarajan K, Nagarwalla N, Ahmed AR. Use of recombinant pemphigus vulgaris antigen in development of ELISA and IB assays to detect pemphigus vulgaris autoantibodies. J Eur Acad of Dermatol and Venereol 1998;10:28-35.

114. Lalani T, Bhol K, Khan IU, Ahmed AR. The Scarring Processes in Mucosal Tissues After Immune Injury. Semin Arthritis Rheum 1998;27:371-81.

115. Khan IU, Bhol KC, Ahmed AR. Linear IgA bullous dermatosis in a patient with chronic renal failure: Response to intravenous immunoglobulin therapy. J Am Acad Dermatol 1999;40:485-8.

116. Chan RY, Bhol L, Tesavibul M, Letko E, Simmons RK, Foster CS, Ahmed AR. The Role of Antibody to Human β4 Integrin in Conjunctival Basement Membrane Separation: Possible In Vitro Model for Ocular Cicatricial Pemphigoid. Invest Ophthalmol Vis Sci 1999;40:2283-90.

117. Foster CS, Ahmed AR. Intravenous Immunoglobulin Therapy for Ocular Cicatricial Pemphigoid: A Preliminary Study. Ophthalmology 1999;106:2136-43.

118. Bhol KC, Rojas AI, Khan IU, Ahmed AR. Presence of Interleukin 10 in the Serum and Blister Fluid of Patients with Pemphigus Vulgaris and Pemphigoid. Cytokine 2000;12:1076-83.

119. Letko E, Bhol K, Foster CS, Ahmed AR. Influence of intravenous immunoglobulin therapy on serum levels of anti-β4 antibodies in ocular cicatricial pemphigoid. A correlation with disease activity. Curr Eye Res 2000;21:646-54.

120. Engineer L, Johnson RE, Bhol KC, Ahmed AR. Bovine gingival lysate: a novel substrate for rapid diagnosis of autoimmune vesiculobullous diseases. A preliminary observation. Exp Dermatol 2000;9:271-4.

121. Letko E, Bhol KC, Foster CS, Ahmed AR. Linear IgA Bullous Disease Limited to the Eye:

         A Diagnostic Dilemma. Response to Intravenous Immunoglobulin Therapy. 

         Ophthalmology 2000;107:1524-8.

122. Bhol KC, Dans MJ, Simmons RK, Foster CS, Giancotti FG, Ahmed AR. The

         Autoantibodies to α6β4 Integrin of Patients Affected by Ocular Cicatricial Pemphigoid

         Recognize Predominantly Epitopes within the Large Cytoplasmic Domain of Human β4. 

         J Immunol 2000;165: 2824-9.

123. Engineer L, Norton LA, Ahmed AR. Nail involvement in pemphigus vulgaris. J Am

         Acad Dermatol 2000;43:529-35.

124. Engineer L, Bhol KC, Ahmed AR. Analysis of current data on the use of intravenous

         immunoglobulins in management of pemphigus vulgaris. J Am Acad Dermatol

         2000;43:1049-57.

125. Engineer L, Ahmed AR. Role of intravenous immunoglobulin in the treatment of bullous

         pemphigoid: analysis of current data. J Am Acad Dermatol 2001;44:83-8.

126. Engineer L, Bhol K, Kumari S, Ahmed AR. Bullous Pemphigoid: Interaction of

         Interleukin-5, Anti-Basement Membrane Zone Antibodies and Eosinophils. A Preliminary

         Observation. Cytokine 2001:13:32-8.

127. Kumari S, Bhol KC, Simmons RK, Razzaque MS, Letko E, Foster CS, Ahmed AR.            Identification of Ocular Cicatricial Pemphigoid Antibody Binding Site(s) in Human β4                                                                       Integrin. Invest Ophthalmol Vis Sci 2001:42:379-85.

128. Colon JE, Bhol KC, Razzaque MS, Ahmed AR. In Vitro Organ Culture Model for Mucous

          Membrane Pemphigoid.  Clin Immunol 2001:98:229-34.

129. Kumari S, Bhol KC, Rehman F, Foster CS, Ahmed AR. Interleukin 1 components in

         cicatricial pemphigoid. Role in intravenous immunoglobulin therapy. Cytokine

         2001;14:218-24.

130. Engineer L, Ahmed AR. Emerging treatment for epidermolysis bullosa acquisita. J Am

         Acad Dermatol 2001;44:818-28.

131. Sami N, Ahmed AR. Penile pemphigus. Arch Dermatol 2001;137:756-8.

132. Letko E, Ahmed AR, Foster CS. Treatment of ocular cicatricial pemphigoid with

         tacrolimus (FK 506). Graefes Arch Clin Exp Ophthalmol 2001;239:441-4.

133. Bhol KC, Goss L, Kumari S, Colon JE, Ahmed AR. Autoantibodies to Human

         α6 Integrin in Patients with Oral Pemphigoid. J Dent Res 2001;80:1711-5.

134. Bhol KC, Desai S, Kumari S, Colon JS, Ahmed AR. Pemphigus Vulgaris: The Role of IL-

         1 and IL-1 Receptor Antagonist in Pathogenesis and Effects of Intravenous

         Immunoglobulin on Their Production. Clin Immunol 2001;100:172-80.

135. Sami N, Bhol KC, Ahmed AR. Diagnostic features of pemphigus vulgaris in patients

         with pemphigus foliaceus: detection of both autoantibodies, long-term follow-up and 

         treatment responses. Clin Exp Immunol 2001;125:492-98.

136. Ahmed AR, Colon JS. Comparison between Intravenous Immunoglobulin and

         Conventional Immunosuppressive Therapy Regimens in Patients with Severe Oral

         Pemphigoid:  Effects on Disease Progression in Patients Nonresponsive to Dapsone

         Therapy. Arch Dermatol 2001;137:1181-9.

137. Ahmed AR. Intravenous immunoglobulin therapy in the treatment of patients with

         pemphigus vulgaris unresponsive to conventional immunosuppressive treatment. J Am 

         Acad Dermatol 2001;45: 679-90.

138. Leverkus M, Bhol K, Hirako T, Pas H, Sitaru C, Baier G, Brocker E-B, Jonkman MF,

         Ahmed AR, Zillikens D.  Cicatricial pemphigoid with circulating autoantibodies to

         β4 integrin, bullous pemphigoid 180 and bullous pemphigoid 230. Br J Dermatol       

         2001;145:998-1004.

139. Ahmed AR. Intravenous immunoglobulin therapy for patients with bullous pemphigoid

         unresponsive to conventional immunosuppressive treatment. J Am Acad Dermatol

         2001;45:825-35.

140. Ahmed AR, Sami N. Intravenous immunoglobulin therapy for patients with pemphigus

         foliaceus unresponsive to conventional therapy. J Am Acad Dermatol 2002;46:42-9.

141. Sami N, Bhol KC, Ahmed AR. Intravenous Immunoglobulin Therapy in Patients with

         Multiple Mucosal Involvement in Mucous Membrane Pemphigoid.  Clin Immunol

         2002;102:59-67.

142. Bhol KC, Ahmed AR. Production of Non-pathogenic Human Monoclonal Antibodies to

         Desmoglein 3 from Pemphigus Vulgaris Patient. Autoimmunity 2002;35:87-91.

143. Razzaque MS, Ahmed AR. Collagens, Collagen-Binding Heat Shock Protein 47 and

         Transforming Growth Factor-β1 are Induced in Cicatricial Pemphigoid:  Possible Role(s)

         in Dermal Fibrosis. Cytokine 2002;17:311-16.

144. Sami N, Qureshi A, Ahmed AR. Steroid sparing effect of intravenous immunoglobulin

         therapy in patients with pemphigus foliaceus.  Eur J Dermatol 2002;12:174-8.

145. Miserocchi E, Baltatzis S, Roque MR, Ahmed, AR, Foster CS. The Effect of Treatment

         and its Related Side Effects in Patients with Severe Ocular Cicatricial Pemphigoid.              Ophthalmology 2002;109:111-8.

146. Ahmed AR, Sami N. Uncommon manifestations of pemphigus vulgaris.  J Eur Acad

         Dermatol Venereol 2002;16:313-5.

147. Letko E, Bhol K, Colon J, Foster CS, Ahmed AR. Biology of interleukin-5 in ocular

         cicatricial pemphigoid.  Graefe’s Arch Clin Exp Ophthalmol 2002;240:565-9.

148. Sami N, Bhol KC, Ahmed AR. Treatment of oral pemphigoid with intravenous

            immunoglobulin as monotherapy.  Long-term follow-up:  influence of treatment on

            antibody titres to human α6 integrin.  Clin Exp Immunol 2002;129:533-40.

149. Razzaque MS, Foster CS, Ahmed AR. Role of Enhanced Expression of m-CSF in  Conjunctiva Affected by Cicatricial Pemphigoid.  Invest Ophthalmol Vis Sci

           2002 ;43:2977-83.

150. Sami N, Qureshi A, Ruocco E, Ahmed AR. Corticosteroid-Sparing Effect of

         Intravenous Immunoglobulin Therapy in Patients with Pemphigus Vulgaris. Arch

Dermatol 2002;138:1158-62.                                                                             

151. Sami N, Bhol KC, and Ahmed AR. Influence of IVIg Therapy on Autoantibody Titers to

         Desmoglein 1 in Patients with Pemphigus Foliaceus. Clin Immunol 2002;105:192-8.    

152. Engineer L, Dow EC, Braverman IM, Ahmed AR. Epidermolysis bullosa acquisita and

         multiple myeloma. J Am Acad Dermatol 2002;47:943-6.

153. Razzaque MS, Kumari S, Foster CS, Ahmed AR. Expression profiles of collagens, HSP47,

         TGF-β1, MMPs and TIMPs in epidermolysis bullosa acquisita. Cytokine 2003;21:207-13.

154. Razzaque MS, Foster CS, and Ahmed AR. Role of Collagen-Binding Heat Shock Protein

         47 and Transforming Growth Factor-β1 in Conjunctival Scarring in Ocular Cicatricial

         Pemphigoid. Invest Ophthalmol Vis Sci 2003;44:1616-21.

155. Bhol KC, Colon JE, and Ahmed AR. Letter to the Editor.  Autoantibody in Mucous

         Membrane Pemphigoid Binds to an Intracellular Epitope on Human β4 Integrin and Causes

         Basement Membrane Zone Separation in Oral Mucosa in an Organ Culture Model. Invest      

         Dermatol 2003;120:701-2.

156. Razzaque MS, Foster CS, and Ahmed AR. Role of Connective Tissue Growth Factor in

         the Pathogenesis of Conjunctival Scarring in Ocular Cicatricial Pemphigoid.  Invest

         Ophthalmol Vis Sci 2003;44:1998-2003.

157. Ahmed AR, Avram MM, and Duncan LM. Case records of the Massachusetts General

         Hospital.  Weekly clinicopathological exercises.  Case 23-2003.  A 79-Year-Old Woman

         with Gastric Lymphoma and Erosive Mucosal and Cutaneous Lesions.  N Engl J Med

         2003;349:382-91.

158. Sami N, Bhol KC, Ahmed AR. Influence of intravenous immunoglobulin therapy on

         autoantibody titers to desmoglein 3 and desmoglein 1 in pemphigus vulgaris.  Eur J

         Dermatol 2003;13:377-81.

159. Razzaque MS, Ahmed BS, Foster CS, and Ahmed AR. Effects of IL-4 on Conjunctival

         Fibroblasts: Possible Role in Ocular Cicatricial Pemphigoid.  Invest Ophthalmol Vis Sci

         2003;44:3417-23.

160. Ahmed AR, Dahl MV; for the Consensus Development Group. Consensus Statement on

         the Use of Intravenous Immunoglobulin Therapy in the Treatment of Autoimmune

         Mucocutaneous Blistering Diseases. Arch Dermatol 2003;139:1051-9.

161. N Sami, S Ali, KC Bhol, AR Ahmed. Influence of intravenous immunoglobulin therapy on            autoantibody  titres to BP Ag1 and BP Ag2 in patients with bullous pemphigoid.  J Eur                                                         Acad Dermatol and Venereal 2003;17:641-645.

162. Razzaque MS, Foster CS, Ahmed AR. Role of Macrophage Migration Inhibitory Factor in

         Conjunctival Pathology in Ocular Cicatricial Pemphigoid.  Invest Ophthalmol Vis Sci

         2004;45:1174-81.

163. Letko E, Miserocchi E, Daoud YJ, Christen W, Foster CS, Ahmed AR. A nonrandomized

         comparison of the clinical outcome of ocular involvement in patients with mucous

         membrane (cicatricial) pemphigoid between conventional immunosuppressive and

         intravenous immunoglobulin therapies. Clin Immunol 2004;111:303-10.

164. Sami N, Letko E, Androudi S, Daoud Y, Foster CS, Ahmed AR. Intravenous

         immunoglobulin therapy in patients with ocular cicatricial pemphigoid:  a long-term

         follow-up.  Ophthalmol 2004;111:1380-82.

165. Yeh SW, Usman AQ, Ahmed AR. Profile of autoantibody to basement membrane

         zone proteins in patients with mucous membrane pemphigoid: long-term follow up and

         influence of therapy. Clin Immunol 2004;112:268-72.

166. Daoud YJ, Cervantes R, Foster CS, and Ahmed AR. Ocular pemphigus.  J Am Acad           Dermatol 2005;53:585-90.

167. Malik M, Ahmed AR. Involvement of the female genital tract in pemphigus vulgaris.          Obstet Gynecol 2005;106:1005-12.

168. Daoud YJ, Foster CS, Ahmed AR. Eyelid Skin Involvement in Pemphigus Foliaceus.  

         Case Report.  Ocul Immunol and Inflamm 2005;13:389-394.

169. Daoud Y, Amin KG, Mohan Krishn, and Ahmed AR. Cost of intravenous

          immunoglobulin therapy versus conventional immunosuppressive therapy in patients

          with mucous membrane pemphigoid:  A preliminary study.  Ann Pharmacother

          2005;39:2003-8.

170. Rashid KA, Stern JN, Ahmed AR. Identification of an epitope within human           integrin α6 subunit for the binding of autoantibody and its role in basement membrane                                                                                    separation in oral pemphigoid. J Immunol 2006;176:1968-77.

171. Malik M, El Tal AE, Ahmed AR. Anal involvement in pemphigus vulgaris.  Dis Colon

         Rectum 2006;49:500-6.

172. Ahmed AR. Future horizons. International Immunopharmacol 2006;6:607-9.

173. Ahmed AR. Use of intravenous immunoglobulin therapy in autoimmune blistering

         diseases.  International Immunopharmacol 2006;6:557-78. 

174. Mignogna M, Lanza A, Rossiello L, Ruocco V, Ahmed AR. Comparison of reactivity

         and epitope recognition between sera from American and Italian patients with oral

         pemphigoid. Clin & Exp Immunol 2006;145:28-35.

175. Rashid KA, Gürcan HM, Ahmed AR. Antigen specificity in subsets of mucous

         membrane pemphigoid. J Invest Dermatol 2006:126:2631-6. 

176. Yeh SW, Cavacini LAS, Bhol KC, Lin MS, Kumar M, Duval M, Posner MR, Ahmed AR.

         Pathogenic human monoclonal antibody against desmoglein 3. Clin Immunol     

         2006;120:68-75.

177. Amagai M, Ahmed AR, Kitajima Y, Bystryn JC, Milner Y, Gniadecki R, Hertl M, Pincelli

         C, Fridkis-Hareli M., Aoyama Y, Frusic-Zlotkin M, Muller E, David M, Mimouni D,

         Vind-Kezumovic D, Michel B, Mahoney M, Grando S.  Controversies in

         Experimental Dermatology.  Are desmoglein autoantibodies essential for the

         immunopathogenesis of pemphigus vulgaris, or just “witnesses of disease’?  Exp Dermatol

         2006;15:815-831. 

178. Ahmed AR, Spigelman Z, Cavacini L, Posner, MR. Treatment of Pemphigus Vulgaris

         with Rituximab and Intravenous Immune Globulin.  N Engl J Med  2006;355:1772-9.

179. Letko E, Bhol K, Anzaar F, Perez VL, Ahmed AR, Foster CS. Chronic Cicatrizing

         Conjunctivitis in a Patient With Epidermolysis Bullosa Acquisita.  Arch Ophthalmol

         2006;124:1615-8.

180. Onal S, Foster CS, Ahmed AR. Efficacy of Intravenous Immunoglobulin Treatment in

         Refractory Uveitis.  Ocul Immunol Inflamm 2006;14:367-74.

181. Guest Editorial. Recent Advances in the Treatment of Autoimmune Mucocutaneous

         Blistering Diseases.  Internat’l J Periodon & Restor Dent 2007;27:309-10.

182. Malik M, Gürcan HM, Christen W, Ahmed AR. Relationship between cancer and oral

         pemphigoid patients with antibodies to alpha6-integrin.  J Oral Pathol Med 2007;36:1-5.

183. Gürcan HM, Ahmed AR. Efficacy of Various Intravenous Immunoglobulin Therapy

         Protocols in Autoimmune and Chronic Inflammatory Disorders.  Ann Pharmacother

         2007;41:812-23.

184. Letko E, Gürcan HM, Papliodis GN, Christen W, Foster CS, Ahmed AR. Relative risk for

         cancer in mucous membrane pemphigoid associated with antibodies to the β4 integrin

         subunit.  Clin Exp Dermatol 2007;32:637-41.

185. Gürcan, Hakan M, and Ahmed, A Razzaque. Frequency of Adverse Events Associated 

         with Intravenous Immunoglobulin Therapy in Patients with Pemphigus or Pemphigoid.

         Ann Pharmacother 2007;41:1604-10.

186. Keskin, DB, Stern JNH, Fridkis-Hareli M, Ahmed, AR. Cytokine profile in pemphigus

         vulgaris patients treated with intravenous immunoglobulins as compared to conventional

         immunosuppressive therapy. Cytokine 2008;41:315-321.

187. Stern JN, Keskin DB, Barteneva N, Zuniga J, Yunis EJ, Ahmed AR. Possible role of

         natural killer cells in pemphigus vulgaris – preliminary observations.  Clin Exp Immunol

         2008;152:472-81.

188. Dedee F, Murrell DF, Dick S, Ahmed AR, Amagai M, Barnadas MA, Borradori L,

         Brystryn JC, Cianchini G, Diaz L, Fivenson D, Hall R, Harman KE, Hashimoto T, Hertl M,

         Hunzelmann N, Iranzo P, Joly P, Jonkman MF, Kitajima Y, Korman NJ, Martin LK,

         Mimouni D, Pandya AG, Payne AS, Rubenstein D, Shimizu H, Sinha AA, Sirois D,

         Zillikens D, Werth VP.  Consensus statement on definitions of disease, end points, and

         therapeutic response for pemphigus.  J Am Acad Dermatol 2008;58:1043-6.

189. Asarch A, Ahmed AR. Treatment of juvenile pemphigus vulgaris with 

         intravenous immunoglobulin therapy.  Pediatr Dermatol 2009;26:197-202.

190. S. Leuci, D. Levine, J. Zhang, Ahmed AR. Response in patients with pemphigus

         Vulgaris to rituximab therapy.  Basis of the biology of B cells.  Gital Dermatol Venereol

         2009;144:379-409.

191. Gürcan HM, Ahmed AR. Intravenous immunoglobulin treatment in laryngeal

          pemphigoid. Clin Exp Dermatol 2009;34:884-6.

192. Malik M, Gürcan HM, Ahmed AR. Coexistence of mucous membrane pemphigoid and

         connective-tissue disease. Clin Exp Dermatol 2010;35:156-9.

193. Zakka LR, Keskin DB, Reche P, Ahmed AR. Relationship between target antigens and

major histocompatibility complex (MHC) class II genes in producing two pathogenic antibodies simultaneously. Clin Exp Immunol 2010;162:224-36.

194. Foster CS, Chang PY, Ahmed AR. Combination of rituximab and intravenous

         immunoglobulin for recalcitrant ocular cicatricial pemphigoid: A prelimary report.

         Ophthalmology 2010;117:861-9.

195. Letko E, Bhol K, Foster CS, Ahmed AR. Possible in vitro model of toxic epidermal

         necrolysis. Arch Ophthalmol 2011;129:666-7.      

196. Mabrouk D, Gürcan HM, Keskin DB, Christen WG, Ahmed AR. Association between

         cancer and immunsouppressive therapy—analysis of selected studies in pemphigus and

         pemphigoid. Ann Pharmacother 2010; 44:1770-6.

197. Feldman R, Ahmed AR. Relevance of rituximab therapy in pemphigus vulgaris: analysis of

         current data and the immunologic basis for its observed responses. Expert Rev. Clin.

         Immunol 2011;7:529-541.

198. Ahmed AR, Gürcan HM. Use of intravenous immunoglobulin therapy during pregnancy in

         patients with pemphigus vulgaris. J Eur Acad Dermatol Venereol 2011;25:1073-9.

199. Zakka LR, Reche P, Ahmed AR. Role of MHC Class II genes in the pathogenesis of Pemphigoid. Autoimmun Rev 2011;11:40-7.

200. Zakka LR, Fradkov E, Keskin DB, Tabansky I, Stern JN, Ahmed AR. The role of natural killer cells in autoimmune blistering diseases. Autoimmunity 2012;45:44-54.

201. Zakka LR, Reche P, Ahmed AR. The molecular basis for the presence of two autoimmune diseases occuring simultanesouly—Preliminary observations based on computer analysis. Autoimmunity 2012;45:253-63.

202. Ahmed AR, Gürcan HM. Treatment of epidermolysis bullosa acquisita with intravenous

         immunoglobulin in patients non-responsive to conventional therapy: Clinical outcome and

         post-treatment long-term follow-up. J Eur Acad Dermatol Venereol 2012;26:1074-83.

203. Feldman RJ, Christen WG, Ahmed AR. Comparison of immunological parameters in patients with pemphigus vulgaris following rituximab and IVIg therapy. Br J Dermatol   2012;166:511-17.

204. Zakka LR, Shetty S, Ahmed AR. Rituximab in the treatment of pemphigus vulgaris.

         Dermatol Ther 2012;2:17.

205. Rashid KA, Foster CS, Ahmed AR. Identification of epitopes within integrin b4 for binding of auto-antibodies in ocular cicatricial and mucous membrane pemphigoid: preliminary report. Invest Ophthalmol Vis Sci 2013;54:7707-7716.

206. Shetty S, Ahmed AR. Treatment of bullous pemphigoid with Rituximab: Critical analysis of the current literature. J Drugs Dermatol 2013;12(6):672-677.

207. Ahmed AR. Management of autoimmune bullous diseases: Pharmacology and therapeutics. (AAD 75^th Anniversary Article) J Am Acad Dermatol 2013;69:476-7.

208. Shetty S, Ahmed AR. Preliminary analysis of mortality associated with rituximab use in autoimmune diseases. Autoimmunity 2013;46:487-496.

209. Rabelo DF, Nguyen T, Caulfield BA, Ahmed, AR. Mucous membrane pemphigoid in two half-sisters.  The potential roles of autointibodies to b4 integrin subunits and HLA-DQb1*0301. J Dermatol Case Rep 2014;1:9-12.

210. Nguyen T, Ahmed AR. Pemphigus vulgaris localized to the tongue.  J Dermatol Case Rep 2014; 2:55-57

211. Nguyen T, Kwan JM, Ahmed AR. Relationship between radiation therapy and bullous pemphigoid. Dermatology 2014; 229: 88-96.

212. Ahmed AR, Shetty S. The emerging role of rituximab in autoimmune blistering diseases.

        Am J Clin Dermatol 2015;16:167-77.

213. Ahmed AR, Kaveri S, Spigelman Z. Long-term remissions in recalcitrant pemphigus

         vulgaris. N Engl J med 2015;373:2693-4.

214. Nguyen T, Alraqum E, Razzaque Ahmed. Positive clinical outcome with IVIg as

        monotherapy in recurrent pemphigoid gestationis. Int Immunopharmacol 2015;26:1-3.

215. Ahmed AR, Shetty S, Kaveri S, Spigelman Z. Treatment of recalcitrant bullous pemphigoid

        (BP) with a novel protocol: a retrospective study with a 6-year follow-up. J Am Acad  

        Dermatol 2016;74:700-8.

216. Ahmed AR, Nguyen T, Kaveri S, Spigelman Z. First line treatment of pemphigus vulgaris

        with a novel protocol in patients with contraindications to systemic corticosteroids and   

        immunosuppressive agents: Preliminary retrospective study with a seven year follow-up. Int   

        Immunopharmacol 2016;34:25-31.

217. Nguyen T, Ahmed AR. Positive clinical outcome in a patient with recalcitrant bullous

pemphigoid treated with rituximab and intravenous immunoglobulin. Clin Exp Dermatol 2017;42:516-19.

218. Ahmed AR, Kaveri S. Reversing Autoimmunity: Combination of Rituximab and

Intravenous Immunoglobulin.  Front Immunol. 2018;18: 9:1189.doi: 10.3389/fimmu.2018.01189.

219. Deverapalli S, Ahmed AR. Anti-laminin-γ-1 pemphigoid: A missing link between bullous

         pemphigoid and mucous membrane pemphigoid. J Am Acad Dermatol. 2018;79:AB44.

        doi: 10.1016/J.JAAD.2018.05.217

220. Turkowski Y, Razvi S, Ahmed AR. Pyoderma gangrenosum-like lesion secondary

        to methylenetetrahydrofolate reductase mutation: an unusual presentation of a rare disease.

        British Medical Journal. 2019;23:12:e228403.

221. Rana Abdat, Reid A Waldman, Valeria de Bedout, Annette Czernik , Michael Mcleod,

        Brett King, Samantha Gordon, Razzaque Ahmed, Anna Nichols, Marti Rothe, David

        Rosmarin. Dupilumab as a novel therapy for bullous pemphigoid: A multicenter case series. 

        Journal of the American Academy of Dermatology. 2020;83:46-52.

222. Kridin K, Ahmed AR. The evolving role of rituximab in the treatment of pemphigus

        vulgaris: a comprehensive state-of-the-art review. Expert Opin Biol Ther. 2021;21:443-454.

        doi: 10.1080/1472598.2021.1874915. PMID: 33455478

223. Ahmed AR, Aksoy M. IgM Deficiency in Autoimmune Blistering Mucocutaneous Diseases

following various treatments: Long-term follow-up and relevant observations.

Front Immunol. 2021;12:727520. doi: 10.3389/fimmu.2021.727520. PMID: 34646266